[1]陈军平.不同用药途径的糖皮质激素对慢性阻塞性肺疾病急性加重患者气道微生态的影响[J].医学信息,2023,36(13):155-158.[doi:10.3969/j.issn.1006-1959.2023.13.034]
　CHEN Jun-ping.Effects on Glucocorticoids with Different Routes of Administration on Airway Microecology in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2023,36(13):155-158.[doi:10.3969/j.issn.1006-1959.2023.13.034]
点击复制

不同用药途径的糖皮质激素对慢性阻塞性肺疾病急性加重患者气道微生态的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年13期
页码:
155-158
栏目:
论著
出版日期:
2023-07-01

文章信息/Info

Title:
Effects on Glucocorticoids with Different Routes of Administration on Airway Microecology in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2023）13-0155-04
作者:
陈军平
（安福县人民医院急诊科，江西 安福 343299）
Author(s):
CHEN Jun-ping
(Emergency Department of Anfu County People’s Hospital,Anfu 343299,Jiangxi,China)
关键词:
慢性阻塞性肺疾病急性加重; 糖皮质激素; 雾化给药; 口服治疗; 肺功能
Keywords:
Acute exacerbation of chronic obstructive pulmonary disease; Glucocorticoids; Aerosol administration; Oral therapy; Pulmonary function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2023.13.034
文献标志码:
A
摘要:
目的 分析不同用药途径的糖皮质激素对慢性阻塞性肺疾病急性加重（AECOPD）患者气道微生态的影响。方法 以2019年2月-2022年2月安福县人民医院收治的60例AECOPD患者为研究对象，采用随机数字表法分为雾化组（30例）与口服组（30例），雾化组给予布地奈德雾化治疗，口服组应用醋酸泼尼松龙片口服治疗，比较两组肺功能[1 s用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC]、血气指标[动脉血氧饱和度（SaO2）、动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）]、血清炎症指标[超敏C反应蛋白（hs-CRP）、白细胞介素-８（IL-8）]、气道微生态（Shannon指数、Simpson指数）、不良反应。结果 两组治疗后FVC、FEV1、FEV1／FVC、SaO2、PaO2均高于治疗前，PaCO2、hs-CRP、IL-6低于治疗前，差异有统计学意义（P＜0.05），但组间比较，差异无统计学意义（P＞0.05）。两组治疗后Shannon指数高于治疗前，Simpson指数低于治疗前，且雾化组Shannon指数高于口服组，Simpson指数低于口服组，差异有统计学意义（P＜0.05）；雾化组不良反应发生率小于口服组，差异有统计学意义（P＜0.05）。结论 雾化吸入与口服使用糖皮质激素治疗AECOPD均可获得确切效果，二者对机体肺功能、血气指标及炎症水平的改善作用相当，其中雾化给药引起的不良反应更少，但其对气道微生态多样性的影响相对较大。
Abstract:
Objective To analyze the effects of glucocorticoids with different routes of administration on airway microecology in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods Sixty patients with AECOPD admitted to Anfu County People’s Hospital from February 2019 to February 2022 were selected as the research objects. They were divided into atomization group (30 patients) and oral group (30 patients) by random number table method. The atomization group was treated with budesonide atomization, and the oral group was treated with prednisolone acetate tablets orally. The pulmonary function [1 s forced expiratory volume (FEV1), forced vital capacity (FVC), FEV1/FVC], blood gas indexes [blood oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2), partial pressure of carbon dioxide in arterial blood (PaCO2)], serum inflammatory indexes [hypersensitive C-reactive protein (hs-CRP), interleukin-8 (IL-8)], airway microecology (Shannon index, Simpson index) and adverse reactions were compared between the two groups.Results After treatment, FVC, FEV1, FEV1/FVC, SaO2 and PaO2 in the two groups were higher than those before treatment, PaCO2, hs-CRP and IL-6 were lower than those before treatment, and the differences were statistically significant (P<0.05); However, there was no significant difference between the two groups (P>0.05). The Shannon index of the two groups after treatment was higher than that before treatment, and the Simpson index was lower than that before treatment, while the Shannon index of the atomization group was higher than that of the oral group, and the Simpson index of the atomization group was lower than that of the oral group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the atomization group was lower than that in the oral group, and the difference was statistically significant (P<0.05).Conclusion Both aerosol inhalation and oral use of glucocorticoids can achieve definite results in the treatment of AECOPD, and the improvement of lung function, blood gas index and inflammatory level is equivalent. The adverse reactions caused by aerosol administration are significantly less, but its impact on airway microecological diversity is relatively large.

参考文献/References:

[1]邓永明,刘洪玲,林盛翠.慢性阻塞性肺疾病急性加重期糖皮质激素治疗疗效观察[J].国际呼吸杂志,2017,37(16):1216-1218.[2]Li Y,Xu Z,Qing C,et al.Clinical efficacy of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].American Journal of Translational Research,2021,13(6):7029-7034.[3]陈亚红.2022年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J].中国全科医学,2022,25(11):1294-1304,1308.[4]杨春兰,杨云,李胜前,等.呼吸内科住院患者糖皮质激素药物使用情况调查分析[J].川北医学院学报,2018,33(4):617-620.[5]齐玉晶.不同用药途径的糖皮质激素对慢阻肺急性加重患者气道微生态的影响[D].南宁:广西医科大学,2019.[6]赵启文,侯欣,高芳.吸入性糖皮质激素在慢性阻塞性肺疾病急性加重期患者中的应用疗效分析[J].山西医药杂志,2020,49(18):2479-2481.[7]国家卫生健康委员会急诊医学质控中心,中华医学会急诊医学分会,中国医师协会急诊医师分会,等.中国慢性阻塞性肺疾病急性加重中西医诊治专家共识(2021)[J].中华危重病急救医学,2021,33(11):1281-1290.[8]赵雅婷,张焕萍.糖皮质激素不同给药方式对哮喘急性发作患者气道炎症的影响[J].山西医科大学学报,2019,50(6):789-793.[9]赵建,严婷,倪英.糖皮质激素不同给药方式治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].中国医院用药评价与分析,2019,19(2):161-163,167.[10]厉旭光,盖磊,周红瑜,等.噻托溴铵联合糖皮质激素治疗慢性阻塞性肺疾病的临床研究[J].实用药物与临床,2018,21(11):1236-1239.[11]张四维,刘登河,詹茂芹.糖皮质激素对慢性阻塞性肺疾病急性发作期患者肺功能及血清ApoA-Ⅰ、ApoB浓度有改善作用[J].内科急危重症杂志,2021,27(4):340-342.[12]王洪群,王兴胜.糖皮质激素不同给药途径剂量及疗程对慢性阻塞性肺疾病急性加重期的影响[J].中华肺部疾病杂志,2018,11(3):370-372.[13]李成博,刘璐,海鑫.糖皮质激素联合复方异丙托溴胺治疗慢性阻塞性肺疾病急性加重期的效果及对血清炎性因子水平的影响[J].四川医学,2018,39(3):316-319.[14]徐琳琳,周瑞清,郑法德,等.糖皮质激素联合特布他林雾化吸入治疗慢性阻塞性肺疾病急性加重患者的临床疗效及其对肺功能的影响[J].实用心脑肺血管病杂志,2021,29(7):18-23.[15]张爱荣.慢性阻塞性肺疾病急性加重期患者应用特布他林联合糖皮质激素治疗的临床疗效及安全性[J].山西医药杂志,2017,46(19):2376-2377.[16]张毅,朱涛,于化鹏.全身性和吸入性糖皮质激素治疗对AECOPD系统性炎症反应水平的影响[J].西部医学,2018,30(1):52-55.[17]吴胜,饶平,吴清松.两种糖皮质激素给药方案治疗老年AECOPD患者的临床观察[J].中国药房,2017,28(14):1972-1975.[18]潘琨.糖皮质激素在慢性阻塞性肺疾病治疗中的作用[J].中国慢性病预防与控制,2017,25(4):316-318.[19]李静,刘红梅,肖文香.糖皮质激素联合沙丁胺醇雾化吸入对慢阻肺急性加重期患者的疗效及肺功能、炎症因子的影响[J].海南医学,2021,32(16):2062-2065.[20]孙虎,左蕾,叶远征,等.全身应用糖皮质激素对慢性阻塞性肺疾病急性加重患者治疗效果的系统评价[J].中国呼吸与危重监护杂志,2017,16(1):1-8.

相似文献/References:

[1]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,31(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
　ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Journal of Medical Information,2018,31(13):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[2]唐培渊,宋俊峰,秦克乐,等.难治性特发性血小板减少性紫癜的治疗进展[J].医学信息,2018,31(05):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
　TANG Pei-yuan,SONG Jun-feng,QIN Ke-le,et al.Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura[J].Journal of Medical Information,2018,31(13):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
[3]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Journal of Medical Information,2018,31(13):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[4]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
　KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Journal of Medical Information,2018,31(13):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[5]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(13):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[6]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
　LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Journal of Medical Information,2018,31(13):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[7]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
　CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Journal of Medical Information,2018,31(13):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[8]高 鹏,高 浩,燕 飞.坏疽性脓皮病1例[J].医学信息,2019,32(01):191.[doi:10.3969/j.issn.1006-1959.2019.01.063]
[9]马艳艳,刘建军.肌无力危象的治疗研究进展[J].医学信息,2019,32(06):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
　MA Yan-yan,LIU Jian-jun.Progress in the Treatment of Myasthenia Crisis[J].Journal of Medical Information,2019,32(13):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
[10]谢卫强,巩 栋,高明暄,等.关节病性银屑病伴髋关节结核1例[J].医学信息,2019,32(07):189.[doi:10.3969/j.issn.1006-1959.2019.07.062]
[11]刘霖杰,袁晓梅.嗜酸性粒细胞在慢性阻塞性肺疾病中的研究现状[J].医学信息,2023,36(18):179.[doi:10.3969/j.issn.1006-1959.2023.18.037]
　LIU Lin-jie,YUAN Xiao-mei.Research Status of Eosinophils in Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2023,36(13):179.[doi:10.3969/j.issn.1006-1959.2023.18.037]

更新日期/Last Update: 1900-01-01